New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
07:54 EDTZGNXZogenix weakness creates buying opportunity, says Oppenheimer
Oppenheimer believes that the recent weakness in Zogenix has been caused by media headlines that rehashed the controversy regarding the approval of its Zohydro drug, as well as a misunderstanding of the company's comments regarding its use of cash. The firm does not expect the FDA to reverse its approval of the drug, and it views the change in the company's Q4 EPS as a result of a non-cash charge as " an accounting artifact." The firm keeps a $5 price target and Outperform rating on the stock.
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
08:35 EDTZGNXZogenix submits modified formulation of Zohydro ER for FDA review
Subscribe for More Information
September 18, 2014
16:27 EDTZGNXZogenix gets exclusive licensing for Zohydro ER from Daravita
Subscribe for More Information
08:40 EDTZGNXZogenix reports new data shows Zohydro ER reduced pain, improved function
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use